Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.760
-0.110 (-2.84%)
Mar 5, 2026, 4:00 PM EST - Market closed
Grace Therapeutics Employees
Grace Therapeutics had 6 employees as of March 31, 2025. The number of employees increased by 2 or 50.00% compared to the previous year.
Employees
6
Change (1Y)
2
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$996,500
Market Cap
58.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| ImmuCell | 84 |
| InflaRx | 74 |
| BeyondSpring | 40 |
| eXoZymes | 31 |
| Entera Bio | 22 |
| NeurAxis | 21 |
GRCE News
- 8 days ago - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 21 days ago - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 4 months ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 5 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire
- 6 months ago - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - GlobeNewsWire